loader from loading.io
πŸ’“ Genes, Gradients, and Game-Changers: FAQs on Hypertrophic Cardiomyopathy show art πŸ’“ Genes, Gradients, and Game-Changers: FAQs on Hypertrophic Cardiomyopathy

Dr. Baliga's 'Podkasts for Curious Docs'

🧠 Hypertrophic Cardiomyopathy β€” A Masterclass from Eugene Braunwald 🧬   πŸ“Œ Just published in NEJM (Aug 2025): a sweeping, state-of-the-art review on HCM β€” from Teare’s first autopsy to myosin inhibitors, AI diagnostics, and gene therapy.   πŸ’₯ Clinical insights, historical depth, trial data (EXPLORER-HCM, SEQUOIA-HCM, VALOR-HCM), and future-facing advancesβ€”all distilled into one must-read.   πŸ“‰ SCD prevention, πŸ«€ LVOT obstruction, πŸ§ͺ MYBPC3/MYH7 mutations, 🧬 proteomics, and more.   πŸ”— Essential reading for cardiologists, geneticists, and...

info_outline
πŸ”¬ Silence APOC3, Slash Triglycerides, A New Era in Triglyceride Control show art πŸ”¬ Silence APOC3, Slash Triglycerides, A New Era in Triglyceride Control

Dr. Baliga's 'Podkasts for Curious Docs'

🚨 New NEJM Study on Olezarsen 🚨 In patients with moderate hypertriglyceridemia and elevated cardiovascular risk, monthly subcutaneous olezarsen reduced triglycerides by over 60% at 6 months! πŸ“‰πŸ’₯   βœ… Significant drops in APOC3, VLDL, remnant & non-HDL cholesterol βœ… No rise in LDL-C βœ… Well-tolerated with mild injection-site reactions   πŸ”¬ APOC3 inhibition emerges as a game-changer in lipidology. πŸ“– ESSENCE–TIMI 73b Trial | Funded by Ionis Pharmaceuticals   #Cardiology #LipidLowering #PrecisionMedicine #NEJM #Olezarsen #TGlowering #CVRisk #TIMI...

info_outline
Dr RR Baliga's Philosophical Discourses: Dogen (Japan, 1200–1253 CE) – Founder of Soto Zen show art Dr RR Baliga's Philosophical Discourses: Dogen (Japan, 1200–1253 CE) – Founder of Soto Zen

Dr. Baliga's 'Podkasts for Curious Docs'

🌸 Dōgen Zenji (1200–1253), founder of the Sōtō Zen school in Japan, taught that true practice lies in zazenβ€”β€œjust sitting” πŸ§˜β€β™‚οΈβ€”where enlightenment and practice are inseparable. His Shōbōgenzō continues to inspire mindfulness & presence today. ⏳✨ #Zen #Mindfulness

info_outline
NSTEMI: πŸ“‰ Less Ischemia, Less Reintervention show art NSTEMI: πŸ“‰ Less Ischemia, Less Reintervention

Dr. Baliga's 'Podkasts for Curious Docs'

🚨 New Evidence in NSTEMI Care! πŸ«€ The SLIM Trial shows that FFR-guided complete revascularization during the index procedure in patients with NSTEMI and multivessel disease significantly reduces death, MI, stroke, and repeat PCI compared to culprit-only PCI.   🎯 Key win? Fewer revascularizations, better outcomes β€” physiology beats anatomy again.   πŸ“š Published in JAMA, presented at #ESC2025 πŸ”— Read more: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.16189 #Cardiology #NSTEMI #FFR #InterventionalCardiology #EvidenceBasedMedicine #SLIMTrial

info_outline
Real-World Rx πŸ’Š, Real Results πŸ“‰: GLP-1 Agents Slash HFpEF Risk show art Real-World Rx πŸ’Š, Real Results πŸ“‰: GLP-1 Agents Slash HFpEF Risk

Dr. Baliga's 'Podkasts for Curious Docs'

πŸ’₯ Practice-Changing Evidence in HFpEF! πŸ’₯ In a real-world cohort of 97,000+ patients with obesity & type 2 diabetes, semaglutide and tirzepatide reduced risk of heart failure hospitalization or death by over 40% πŸ“‰ βš–οΈ No meaningful difference between the two agents. 🧠 Findings reinforce STEP-HFpEF & SUMMIT trials and highlight GLP-1 therapies’ expanding role in cardiometabolic HFpEF πŸ«€ #Cardiology #HFpEF #GLP1 #Semaglutide #Tirzepatide #T2DM #RealWorldEvidence #JAMA #HeartFailure

info_outline
 The AMALFI AF Screening Trial-πŸ“ˆ Atrial Fibrillation Unmasked: A Modest Win for Mailed Monitors show art The AMALFI AF Screening Trial-πŸ“ˆ Atrial Fibrillation Unmasked: A Modest Win for Mailed Monitors

Dr. Baliga's 'Podkasts for Curious Docs'

πŸ“’ Just read the #AMALFI trial in JAMA πŸ“° β€” a landmark remote RCT of AF screening using 14-day ECG patches mailed to older adults at stroke risk πŸ“¦πŸ«€. At 2.5 years, the patch group had a modestly higher AF detection rate (6.8% vs 5.4%, p=0.03) and increased anticoagulation use πŸ’ŠπŸ§ . Stroke rates were similar βš–οΈ.   🎯 Key takeaway: Remote, mail-based AF screening is feasible and nudges diagnosis rates β€” but will it move the needle on outcomes?   #AFib #StrokePrevention #RemoteMonitoring #ECG #Cardiology #RCT #JAMA #DigitalHealth #Geriatrics πŸ§“πŸ“‰

info_outline
πŸ›‘ AFib Gone, OAC Gone? ALONE-AF Challenges Lifelong Therapy show art πŸ›‘ AFib Gone, OAC Gone? ALONE-AF Challenges Lifelong Therapy

Dr. Baliga's 'Podkasts for Curious Docs'

🚨 New Trial Alert 🚨 Can we safely stop anticoagulation after AF ablation? The ALONE-AF Trial πŸ«€ suggests yesβ€”in selected patients with no AF recurrence, stopping DOACs reduced major bleeding 🌟 without increasing stroke risk 🧠.   πŸ“‰ 0.3% vs 2.2% for the composite outcome (P = .02) πŸ“ Carefully monitored, low-risk patients may benefit most.   πŸ“ Editorial: Recommends shared decision-making 🀝 & individualized rhythm monitoring. πŸ“š A potential shift in post-ablation care.   πŸ”— #AFib #Anticoagulation #EPTrials #CardioTwitter #StrokePrevention #JAMA...

info_outline
πŸ¦ πŸ’”Bugged After the Heartbreak?  Does H. pylori Screening After MI Prevent GI Bleeds? show art πŸ¦ πŸ’”Bugged After the Heartbreak? Does H. pylori Screening After MI Prevent GI Bleeds?

Dr. Baliga's 'Podkasts for Curious Docs'

🚨 New Findings from the HELP-MI Trial! πŸ‡ΈπŸ‡ͺπŸ§ͺ Can routine Helicobacter pylori screening during acute myocardial infarction (MI) hospitalization prevent upper gastrointestinal bleeding (UGIB)?   πŸ’‰ Over 18,000 patients across 35 Swedish hospitals πŸ“‰ Result: No significant reduction in UGIB overall (RR 0.90; P=0.18) πŸ” BUT: Clear benefit in patients with anemia (RR 0.44–0.64) and chronic kidney disease (RR 0.75)   🧠 Key Takeaway: Routine screening isn’t broadly warrantedβ€”but targeted testing in high-risk AMI patients may be the smarter path forward.   πŸ“Š...

info_outline
🧬 Risk, Recurrence, Relief: Apixaban’s Edge in VTE 🌑️  Emphasizes the risk stratification, recurrence data, and therapeutic benefit show art 🧬 Risk, Recurrence, Relief: Apixaban’s Edge in VTE 🌑️ Emphasizes the risk stratification, recurrence data, and therapeutic benefit

Dr. Baliga's 'Podkasts for Curious Docs'

🩺 New Insights on Apixaban for VTE! πŸ“’ The HI-PRO trial challenges the old 3-month rule for provoked VTE. πŸ“‰ Extended low-dose apixaban (2.5 mg BID) reduced recurrent VTE from 10.0% ➑️ 1.3% with minimal major bleeding. 🎯 Editorial in NEJM urges a shift from binary labels (β€œprovoked vs unprovoked”) to a patient-centered, risk-adapted approach. 🧠 Art meets evidence in the decision to extend anticoagulation. πŸ’¬ Let’s rethink how we label, risk-stratify, and treat.   πŸ“š #VTE #Apixaban #Anticoagulation #NEJM #HI_PRO #Thrombosis #PrecisionMedicine...

info_outline
Dr RR Baliga's Philosophical Discourses: Zhu Xi (China, 1130–1200 CE) – Neo-Confucian Philosopher show art Dr RR Baliga's Philosophical Discourses: Zhu Xi (China, 1130–1200 CE) – Neo-Confucian Philosopher

Dr. Baliga's 'Podkasts for Curious Docs'

🌏 Zhu Xi (1130–1200), a master of Neo-Confucianism, reshaped Chinese philosophy with his focus on rationality, self-cultivation & education. His commentaries on the Four Books guided civil service exams for centuries across East Asia. πŸ“šβœ¨   #Leadership #Philosophy #History #Confucianism

info_outline
 
More Episodes

πŸ”¬ Anemia & Folate: Key Insights

 

🩸 Anemia is primarily caused by iron deficiency in the U.S., especially in pregnancy (30% prevalence).

πŸ“Š NHANES data shows high iron deficiency in young females (up to 77.5% at ferritin <50 ΞΌg/L).

⚠️ Causes include heavy menstrual loss, increased pregnancy needs, and low dietary heme iron.

πŸ’Š Iron supplements (18 mg/day) help, but >45 mg/day may cause nausea & constipation.

πŸ‘Ά Maternal iron status affects infant birth weight, and delayed cord clamping improves newborn iron stores.

🌍 In low-income countries, anemia is also linked to malaria, parasites, and hemoglobinopathies.

🍞 Folic acid fortification since 1998 has reduced neural-tube defects, making folate deficiency rare in the U.S.